Letrozol Tolife (Letrozole)

Letrozol Tolife is an aromatase inhibitor indicated for hormone‑dependent breast cancer treatment.

• Hormone receptor‑positive breast cancer in postmenopausal women: reduces tumor growth by decreasing estrogen synthesis.
• Adjuvant therapy after surgery for early‑stage breast cancer: lowers risk of disease recurrence.
• Metastatic breast cancer in postmenopausal patients: helps control disease progression when other endocrine therapies are unsuitable.

• Letrozole selectively inhibits the aromatase enzyme (CYP19A1), which converts androgens to estrogens in peripheral tissues. By blocking this conversion, systemic estrogen levels decline, depriving estrogen‑dependent tumor cells of growth stimulation. The drug acts primarily in adipose tissue, liver, and breast tissue, leading to reduced estrogen‑mediated signaling pathways that drive proliferation of hormone‑sensitive cancer cells.

Common side effects are generally mild to moderate and reflect reduced estrogen activity.

Common Side Effects

• Hot flashes: sudden feeling of warmth and sweating.
• Joint and muscle pain: aching in joints or muscles.
• Fatigue: persistent tiredness.
• Nausea: mild stomach upset.
• Headache: occasional throbbing pain.
• Increased sweating: excessive perspiration.

Serious or Rare Side Effects

• Severe liver injury: jaundice, elevated liver enzymes.
• Bone fractures: increased risk due to bone density loss.
• Pulmonary embolism: sudden shortness of breath, chest pain.
• Elevated cholesterol: significant rise in blood lipids.
• Severe allergic reaction: rash, swelling, difficulty breathing.
• QT interval prolongation: cardiac rhythm disturbances.

Patients should be monitored for specific safety concerns before and during therapy.

• Bone health monitoring: assess bone mineral density regularly.
• Liver function assessment: check hepatic enzymes before initiation and periodically.
• Cardiovascular risk evaluation: review history of thromboembolic events.
• Pregnancy avoidance: do not use in pregnant or breastfeeding women.
• Severe hepatic impairment: avoid or use with caution.
• Store at room temperature: keep in the original packaging, protect from moisture and light.

Letrozole may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Estrogen‑containing hormone therapy: may diminish letrozole efficacy.
• Tamoxifen: antagonistic effect on estrogen pathways.
• Strong CYP2A6 inhibitors (e.g., fluvoxamine): increase letrozole plasma levels.
• Antifungal azoles (e.g., ketoconazole): raise systemic exposure.
• Enzyme‑inducing anticonvulsants (e.g., carbamazepine): lower letrozole concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, monitor coagulation.
• Statins: possible heightened risk of myopathy.
• SSRIs (e.g., fluoxetine): may affect metabolism, observe for side‑effects.
• Thyroid hormone replacement: monitor thyroid function tests.
• Herbal supplements (e.g., St. John’s wort): may alter drug levels.